Market research
IMU.AU Imugene Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- 0.3067
- Dividend yield
- Not available
- Beta
- 2.07
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000IMU9
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- 0.3067
- Dividend yield
- Not available
- Beta
- 2.07
About
About Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and Neo-POLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IMU.AU discussion.
5 years, 5 months ago
Imugene Limited is currently in a long term uptrend where the price is trading 105.5% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Imugene Limited's total revenue rose by 73.1% to $4M since the same quarter in the previous year.
Its net income has dropped by 26.6% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 38.6% to $-2M since the same quarter in the previous year.
Based on the above factors, Imugene Limited gets an overall score of 4/5.